JDRF Blog

Latest in Prevention

  • FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years

    August 5, 2019

    The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay...

  • ADA Scientific Sessions Recap—Day #3.5: Jessica Dunne, Ph.D.

    June 10, 2019

    There was some really exciting prevention research in day #3, and also screening for type 1 diabetes risk. Here is Jessica Dunne,...

  • First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset

    June 9, 2019

    This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immunotherapy demonstrated a...

  • Multiple Benefits of Screening For Beta Cell Autoimmunity in Children

    February 19, 2019

    Normally, our immune system ignores our body’s own safe cells and attacks only dangerous foreign cells. But our bodies create autoantibodies—antibodies against...

  • T1D Diagnosis? Gut Bacteria May Hold the Clue

    February 14, 2019

    Over the past 50 years, type 1 diabetes (T1D) has increased significantly in many developed countries around the world. There is a...

  • JDRF Leads Push to Develop a Vaccine for Viral Infections that Could Trigger T1D

    January 31, 2019

    Scientists worldwide are attempting to determine why some people predisposed to type 1 diabetes (T1D) eventually end up developing the disease. There...

  • JDRF Drives Next-Generation Type 1 Diabetes Research With New Partnerships & Breakthrough Science

    December 22, 2018

    JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced today that it made progressive advances this year on its...

  • Immunology of Diabetes Society Congress Brings World-Renowned Minds to London, England

    October 24, 2018

    Every 18 months, researchers from around the world gather for the Immunology of Diabetes Society (IDS) Congress, which is taking place this...

  • JDRF Top Advances Over the Past Year

    July 5, 2018

    At JDRF, we are committed to funding the development of new therapies to keep people with type 1 diabetes (T1D) healthier, longer,...